Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure i...
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
- Associated Therapies
- -
ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.
- Conditions
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 180
- Registration Number
- NCT00346749
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT00274534
- Locations
- 🇺🇸
Hunter Holmes McGuire Medical Center, Richmond, Virginia, United States
🇺🇸Hines Veterans Administration Hospital, Hines, Illinois, United States
A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 653
- Registration Number
- NCT00274560
- Locations
- 🇺🇸
Temple University School of Medicine, Philadelphia, Pennsylvania, United States
🇬🇷University Hospital of Ioannina, Ioannina, Greece
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
The Effect of Salmeterol on Eosinophil (EOS) Function
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 36
- Registration Number
- NCT00214019
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 87
- Registration Number
- NCT00200967
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸National Jewish Medical & Research Center, Denver, Colorado, United States
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
- Conditions
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 740
- Registration Number
- NCT00144911
- Locations
- 🇨🇦
GSK Investigational Site, Sorel, Quebec, Canada
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
- Conditions
- First Posted Date
- 2005-06-23
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 797
- Registration Number
- NCT00115492
- Locations
- 🇨🇦
GSK Investigational Site, Trois Rivieres, Quebec, Canada
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
- Conditions
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 741
- Registration Number
- NCT00064402
- Locations
- 🇺🇸
Advances in Medicine, Rancho Mirage, California, United States
🇺🇸Office of Bradley Sakran, MD, PC, O'Fallon, Illinois, United States
🇺🇸University of Maryland-Airways Research Center, Baltimore, Maryland, United States
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
- Conditions
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 799
- Registration Number
- NCT00064415
- Locations
- 🇺🇸
Advances in Medicine, Rancho Mirage, California, United States
🇺🇸Inland Clinical Research, Inc., Riverside, California, United States
🇺🇸New Horizon Health Research, Atlanta, Georgia, United States
A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis
- Conditions
- First Posted Date
- 2000-04-14
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00005110
- Locations
- 🇺🇸
Division of Allergy and Pulmonary Medicine, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.